SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Geron Corp.
GERN 1.275+0.4%3:09 PM EDT

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: tktrimbath12/31/2021 8:19:33 PM
1 Recommendation

Recommended By
cycleupcycledown

   of 3535
 
My end of year review of GERN

INTRO Here's my semi-annual exercise to see if I remember why I own the stocks I own, and so I can check back and see if their stories have changed. I post in case it helps others too.

Geron

GERN (market cap is $0.393B was $0.495B)

Geron is a leading edge biotech focused on telomerase treatments dealing with hematological treatments. They continue to make progress to the point that some estimates of more general use are described in a few years rather than the decades it has taken so far. As with many innovative treatments aimed at a narrow portion of a broader illness, approval for one treatment can lead to a multiplying effect as it is applied to similar illnesses. First, fix one.

Geron was working on a wide variety of innovative treatments for decades. They sold off almost everything else. If successful, they may be a headline comeback story and benefit people dealing with few if any options.

I suspect investors familiar with the company and the technology over these years may be sitting and watching for significant, positive news. The company forecasts the commercial launch of imetelstat in lower risk MDS in the United States to be in 2024. Investors won't all wait until full approval, but it is hard to know when or if they will return, hence, I buy now and hold.



DISCLOSURE LTBH since 1999 and continuing to hold. I bought more when they mentioned specific years for clinical trials and approval goals.

(I've also collected links to the other discussion boards and my other stocks over on my blog trimbathcreative.net )
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext